全文获取类型
收费全文 | 1321篇 |
免费 | 121篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 22篇 |
妇产科学 | 21篇 |
基础医学 | 183篇 |
口腔科学 | 16篇 |
临床医学 | 96篇 |
内科学 | 369篇 |
皮肤病学 | 13篇 |
神经病学 | 45篇 |
特种医学 | 10篇 |
外国民族医学 | 1篇 |
外科学 | 101篇 |
综合类 | 101篇 |
预防医学 | 33篇 |
眼科学 | 11篇 |
药学 | 200篇 |
1篇 | |
中国医学 | 17篇 |
肿瘤学 | 247篇 |
出版年
2024年 | 4篇 |
2023年 | 22篇 |
2022年 | 65篇 |
2021年 | 75篇 |
2020年 | 57篇 |
2019年 | 53篇 |
2018年 | 70篇 |
2017年 | 61篇 |
2016年 | 66篇 |
2015年 | 78篇 |
2014年 | 96篇 |
2013年 | 129篇 |
2012年 | 79篇 |
2011年 | 91篇 |
2010年 | 61篇 |
2009年 | 42篇 |
2008年 | 64篇 |
2007年 | 59篇 |
2006年 | 50篇 |
2005年 | 39篇 |
2004年 | 31篇 |
2003年 | 24篇 |
2002年 | 15篇 |
2001年 | 13篇 |
2000年 | 11篇 |
1999年 | 15篇 |
1998年 | 5篇 |
1997年 | 7篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 10篇 |
1993年 | 6篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 8篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1975年 | 5篇 |
1974年 | 3篇 |
1973年 | 4篇 |
1972年 | 6篇 |
1971年 | 4篇 |
1970年 | 6篇 |
1969年 | 3篇 |
排序方式: 共有1496条查询结果,搜索用时 15 毫秒
1.
2.
近年来,随着类风湿性关节炎发病机制及某些致炎因子的发现,出现了一系列新药。环氧合酶-Ⅱ特异性抑制剂与传统的非甾体类抗炎药相比具有疗效好、副作用小的优点;早期联合使用改变病情性抗风湿药在近期内有较好的临床疗效。此外重组可溶性肿瘤坏死因子受体融合蛋白 (etanercept)、人体抗肿瘤坏死因子-α单克隆抗体(adalimumab)和阿那白滞素(anakinra)等生物学治疗及中药治疗均显示了新的治疗前景。 相似文献
3.
P. Cumming T. K. Venkatachalam S. Rajagopal M. Diksic A. Gjedde 《Synapse (New York, N.Y.)》1994,17(2):125-128
The blood-brain permeabilities of L-[3H]tyrosine and the tyrosine hydroxylase (TH) inhibitor β-[14C]methyl-para-tyrosine ([14C]AMPT) were determined in rat striatum, a brain region rich in TH activity, and in other brain regions containing relatively little TH activity. In striatum, the unidirectional clearance rate (K1) for L-[3H]tyrosine (6.2 ml hg- ?1 min?1) was significantly greater than the rates for L-[14C]AMPT (2.8 ml hg?1 min?1) and D-[14C]AMPT (0.8 ml hg?1 min?1). The apparent volume of distribution (Vf) for L-[14C]AMPT in striatum (72.5 ± 4.0 ml hg-1) did not differ from the Vf in other brain regions. The homogeneous distribution of L-[14C]AMPT in rat brain indicates that labeled AMPT is unsuitable for the study of TH in vivo by quantitative autoradiography. © 1994 Wiley-Liss, Inc. 相似文献
4.
Karen W. Gripp Lindsey A. Morse Marni Axelrad Kathryn C. Chatfield Aaron Chidekel William Dobyns Daniel Doyle Bronwyn Kerr Angela E. Lin David D. Schwartz Barbara J. Sibbles Dawn Siegel Suma P. Shankar David A. Stevenson Mihir M. Thacker K. Nicole Weaver Sue M. White Katherine A. Rauen 《American journal of medical genetics. Part A》2019,179(9):1725-1744
Costello syndrome (CS) is a RASopathy caused by activating germline mutations in HRAS. Due to ubiquitous HRAS gene expression, CS affects multiple organ systems and individuals are predisposed to cancer. Individuals with CS may have distinctive craniofacial features, cardiac anomalies, growth and developmental delays, as well as dermatological, orthopedic, ocular, and neurological issues; however, considerable overlap with other RASopathies exists. Medical evaluation requires an understanding of the multifaceted phenotype. Subspecialists may have limited experience in caring for these individuals because of the rarity of CS. Furthermore, the phenotypic presentation may vary with the underlying genotype. These guidelines were developed by an interdisciplinary team of experts in order to encourage timely health care practices and provide medical management guidelines for the primary and specialty care provider, as well as for the families and affected individuals across their lifespan. These guidelines are based on expert opinion and do not represent evidence‐based guidelines due to the lack of data for this rare condition. 相似文献
5.
F. Bussereau C. -H. Dupont E. Boy-Marcotte L. Mallet M. Jacquet 《Current genetics》1992,21(4-5):325-329
Summary The ccs1-1 mutation of Saccharomyces cerevisiae, which has been previously described, is associated with an increase in cytochrome content, in respiration, and in ATP synthesis. In addition, this mutation leads to the same phenotype as cells de-regulated in the cAMP pathway. From a yeast genomic library, we have isolated a DNA fragment in a recombinant plasmid pCD1 which complements the ccs1-1 mutation. Homologous integration of this DNA in the genome occurs at the CCS1 locus. An 11 kb of the DNA insert is necessary for complementation. Sequencing part of the fragment identifies CCS1 as the IRA2 gene. The IRA2 gene is known to encode an attenuator of RAS gene product activity which stimulates the GTPase activity of the RAS proteins. This result underlines the involvement of cAMP-dependent phosphorylation in mitochondrial function. We present the sequence of 1 kb DNA upstream of the putative ATG of the IRA2/CCS1 gene product which is devoid of an ORF and could contain several regulatory sites. 相似文献
6.
Tadashi Terada 《Pathology international》2008,58(12):806-809
Carcinoma arising from Rokitansky–Aschoff sinus (RAS) is extremely rare; only eight cases have been reported in the literature. Herein is reported a case of minute adenocarcinoma arising in RAS. A 77‐year‐old Japanese man with gallbladder stones underwent cholecystectomy. A tiny submucosal tumor (1 cm × 1 cm) was incidentally recognized. Histologically, the submucosal tumor was located in the subserosa and, to a lesser extent, in the fibromuscular layer. It was adenocarcinoma. RAS were recognized within the tumor, and there was a gradual transition between RAS and the adenocarcinoma. Mucin histochemistry indicated neutral and acidic mucins in the cytoplasm and lumens of the adenocarcinoma cells. Immunohistochemistry showed that the adenocarcinoma cells were positive for cytokeratin, epithelial membrane antigen, carbohydrate antigen 19‐9, K‐i67 (labeling = 80%), MUC1, MUC5AC and MUC6. In contrast, the adenocarcinoma cells were negative for CEA, c‐erbB2, p53 protein, MUC2 and CD10. In summary, minute subserosal adenocarcinoma, which arose in RAS, was found incidentally; therefore careful examination of resected gallbladders is necessary. 相似文献
7.
Lee KW Yun T Song EK Na II Shin H Bang SM Lee JH Lee ST Kim JH Yoon SS Lee JS Park S Kim BK Kim NK 《Journal of Korean medical science》2005,20(4):598-562
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3 mg/m2 twice weekly for 2 week in a 3-week cycle). Seven patients were enrolled. The median age of patients was 59 yr. All patients previously received VAD (vincristine, doxorubicin and dexamethasone) and thalidomide chemotherapy. Three patients previously received alkylator-containing chemotherapy and 4 patients, autologous stem cell transplantation. Bortezomib monotherapy resulted in 3 partial remissions (43%), 3 no changes (43%) and 1 progressive disease (14%). One patient who had no response to bortezomib monotherapy experienced partial remission after addition of dexamethasone to bortezomib. The most common serious toxicity was thrombocytopenia (grade 3/4, 10 of 20 cycles (50%)) and grade 3 peripheral neuropathy was developed in 2 of 20 cycles (10%). Drug-related adverse event led to discontinuation of bortezomib in 1 patient. There was no treatment related mortality. Overall, bortezomib seems to be effective and feasible. Conduction of larger clinical studies on Korean patients is necessary to characterize clinical efficacy and safety of bortezomib more precisely. 相似文献
8.
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours 总被引:7,自引:0,他引:7
Sieben NL Macropoulos P Roemen GM Kolkman-Uljee SM Jan Fleuren G Houmadi R Diss T Warren B Al Adnani M De Goeij AP Krausz T Flanagan AM 《The Journal of pathology》2004,202(3):336-340
Genes of the RAF family, which mediate cellular responses to growth signals, encode kinases that are regulated by RAS and participate in the RAS/RAF/MEK/ERK/MAP-kinase pathway. Activating mutations in BRAF have recently been identified in melanomas, colorectal cancers, and thyroid and ovarian tumours. In the present study, an extensive characterization of BRAF and KRAS mutations has been performed in 264 epithelial and non-epithelial ovarian neoplasms. The epithelial tumours ranged from adenomas and borderline neoplasms to invasive carcinomas including serous, mucinous, clear cell, and endometrioid lesions. It is shown that BRAF mutations in ovarian tumours occur exclusively in low-grade serous neoplasms (33 of 91, 36%); these included serous borderline tumours (typical and micropapillary variants), an invasive micropapillary carcinoma and a psammocarcinoma. KRAS mutations were identified in 26 of 91 (29.5%) low-grade serous tumours, 7 of 49 (12%) high-grade serous carcinomas, 2 of 6 mucinous adenomas, 22 of 28 mucinous borderline tumours, and 10 of 18 mucinous carcinomas. Of note, two serous borderline tumours were found to harbour both BRAF and KRAS mutations. The finding that at least 60% of serous borderline tumours harbour mutations in two members of the ERK-MAP-kinase pathway (BRAF 36%, KRAS 30%) compared with 12% of high-grade serous carcinomas (BRAF 0%, KRAS 12%) indicates that the majority of serous borderline tumours do not progress to serous carcinomas. Furthermore, no BRAF mutations were detected in the other 173 ovarian tumours in this study. 相似文献
9.
目的用分子克隆技术构建肝癌组织特异性N-rascDNA正义与反义表达载体.方法用BamHI酶切携带目的基因的质粒pZIP-NeoSV(X)1,获得1.06kbN-rascDNA;同时以BamHI将载体pEBAF线性化,并行去磷酸化修饰,用T4DNA连接酶将两者连接,转化感受态细菌DH5α.先以酶切和随机引物法标记的N-rascDNA探针进行菌落原位杂交筛选阳性重组克隆,再以PvuⅡ酶切鉴定插入方向,同时进行DNA测序和同源性分析.结果成功构建肝癌组织特异性正义与反义表达载体pEBAF/s-N-ras和pEBAF/as-N-ras.结论成功构建的N-rascDNA正/反义表达载体,为原发性肝癌的发生机理和基因治疗研究奠定良好的基础. 相似文献
10.
Summary A method is described for the growth of calcium oxalate dihydrate in normal urine. Soluble chlorophyllin, at a concentration of 20 g/ml inhibited the crystallisation and the growth kinetics of the dihydrate crystals. The inhibitory capacity of chlorophyllin was compared with previous results. Data obtained suggest that the food and drug colourant chlorophyllin might be useful in the treatment of calcium oxalate stone disease. 相似文献